Academic partnering opportunities

IN-PART GLOBAL CHALLENGES

Research interests and approach to industry partnering at the NCI

National Cancer Institute

The National Cancer Institute (NCI) is the United States federal government's principal agency for cancer research and training. The NCI leads the National Cancer Program which conducts and supports research, training, and health information dissemination activities focusing on the cause, diagnosis, prevention, rehabilitation from cancer, and treatment of cancer.

NCI
National Cancer Institute

Research

NCI is the largest funder of cancer research in the world with an annual budget of approximately $5 billion. These funds support research performed at NCI, cancer centers, hospitals, community clinics, and universities. Achieving the NCI's goals of accelerating the rate of scientific discovery and reducing the burden of cancer requires strong and sustained funding for a wide range of research disciplines—from basic science to clinical science to research on implementation and cancer care delivery.

Relevant technologies *(a showcase of some relevant research)*:

- E-107-2020: IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors
  - *Investigator: Mitchell Ho, Ph.D.*
- E-256-2020: Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors
  - *Investigator: Terrence R. Burke, Ph.D.*
- E-182-2019: Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
  - *Investigator: Giovanna Tosato, M.D.*
- E-215-2018: Efficacious Fluorinated Cytidine Analog Cancer Therapeutic With Low Toxicity In Animal Studies
  - *Investigator: Joel Morris, Ph.D.*
- E-167-2017: Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity
  - *Investigator: John T. Schiller, Ph.D.*

Preferred approaches to industry partnerships and support mechanisms:

NCI's Technology Transfer Center's (TTC) Technology Transfer Managers (TTMs) work closely with NIH investigators to negotiate agreements with outside parties for licensing and collaboration opportunities to facilitate technology commercialization to benefit public health. These outside parties include life sciences companies of all sizes, non-profit organizations, and universities. These collaborations support the development of new, innovative technologies and therapeutics.

CONNECT WITH THE NCI